Pretreatment Neutrophil‐to‐Lymphocyte Ratio ( NLR ) Predicts Treatment Toxicity and Intolerance in Operable Head and Neck Cancer: An Ambispective Cohort Study
Head & Neck · 2025
DOI: 10.1002/hed.28212 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Head & Neck, 2025. Verfasst von Raisa Chowdhury und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Neutrophils, Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Pretreatment neutrophil to lymphocyte ratio (NLR) is a negative prognostic marker for survival in head and neck cancer (HNC). Its association with treatment toxicity and intolerance in patients undergoing curative‐intent surgery is unknown.
Methods
Ambispective study of patients with operable stage II–IV, HPV‐negative HNC treated at two academic hospitals. Multiple logistic regression was performed to evaluate the association between pretreatment NLR and short‐term treatment outcomes including treatment toxicity and intolerance.
Results
Among 456 patients, 194 experienced treatment‐related toxicity, defined as grade ≥ 3 adverse events, and 200 exhibited treatment intolerance, defined as treatment discontinuation or delay due to poor tolerance. High pretreatment NLR was significantly associated with an increased risk of toxicity (OR 1.04; 95% CI: 1.00–1.09) and intolerance (OR 1.06; 95% CI: 1.01–1.12). Patients with an NLR < 2.5 had significantly lower odds of experiencing toxicity (OR 0.50; 95% CI: 0.26–0.96) and intolerance (OR 0.57; 95% CI: 0.33–0.99) after adjusting for multiple confounders.
Conclusions
Low pretreatment NLR was associated with reduced treatment toxicity and lower rates of intolerance in patients undergoing curative‐intent surgery for HNC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
- Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
- Department of Medical Oncology, McGill University, Montreal, Quebec, Canada.
- Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada.
- Center for clinical epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
ORCID-Profile: Raisa Chowdhury, Karim Botros
Zitieren
APA
Chowdhury, R., Botros, K., Richardson, K., Mlynarek, A. M., Sadeghi, N., Hier, M. P., Wurzba, S., Esfahani, K., Bouganim, N., Sultanem, K., Shenouda, G., Tsien, C., & Mascarella, M. A. (2025). Pretreatment Neutrophil‐to‐Lymphocyte Ratio ( NLR ) Predicts Treatment Toxicity and Intolerance in Operable Head and Neck Cancer: An Ambispective Cohort Study. Head & Neck. https://doi.org/10.1002/hed.28212
Vancouver
Chowdhury R, Botros K, Richardson K, Mlynarek AM, Sadeghi N, Hier MP, et al. Pretreatment Neutrophil‐to‐Lymphocyte Ratio ( NLR ) Predicts Treatment Toxicity and Intolerance in Operable Head and Neck Cancer: An Ambispective Cohort Study. Head & Neck. 2025. doi:10.1002/hed.28212
BibTeX
@article{Chowdhury2025,
author = {Chowdhury, Raisa and Botros, Karim and Richardson, Keith and Mlynarek, Alex M and Sadeghi, Nader and Hier, Michael P and Wurzba, Sabrina and Esfahani, Khashayar and Bouganim, Nathaniel and Sultanem, Khalil and Shenouda, George and Tsien, Christina and Mascarella, Marco A},
title = {Pretreatment Neutrophil‐to‐Lymphocyte Ratio ( NLR ) Predicts Treatment Toxicity and Intolerance in Operable Head and Neck Cancer: An Ambispective Cohort Study},
journal = {Head & Neck},
year = {2025},
doi = {10.1002/hed.28212}
}
EUVIMED